Answer
Idelalisib inhibits CXCR4 and CXCR5 receptor signalling induced by CXCL12 and CXCL13, respectively, reducing malignant B-cell homing and retention in the tumour microenvironment, including lymphoid tissues and bone marrow.
Sources for this answer
- Zydelig 150mg film-coated tabletsGilead Sciences Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 23Document updated
Sources checked